Method and compositions involving microRNA

• US 8,465,914 B2
• Filed: 07/02/2012
• Issued: 06/18/2013
• Est. Priority Date: 05/28/2004
• Status: Expired due to Fees

• Current Assignee: Asuragen, Inc. (Bio-Techne Corporation)
• Original Assignee: Asuragen, Inc. (Bio-Techne Corporation)
• Inventors: Brown, David, Conrad, Rick, Devroe, Eric, Goldrick, Marianna, Keiger, Kerri, Labourier, Emmanuel, Moon, Ivonne, Powers, Patricia, Shelton, Jeffrey, Shingara, Jaclyn
• Primary Examiner(s): Chong, Kimberly
• Application Number:
  US13/540,413
• Publication Number:
  US 20130017972A1
• Time in Patent Office: 351 Days
• Field of Search: None
• US Class Current: 435/6
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/3517 Marker; Tag
• CPC Class Codes: C12N 2310/3519 Fusion with another nucleic acid
• CPC Class Codes: C12N 2320/10 in screening processes
• CPC Class Codes: C12P 19/34 Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2525/207 siRNA, miRNA
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.

Claims

1. A method for evaluating a thyroid sample in a patient comprising:

a) measuring the expression level of miR-21 in the sample;

b) comparing the expression level to the expression level of the same miRNAs in a noncancerous thyroid sample; and

,

c) identifying the patient as having a marker for thyroid cancer if the sample is determined to have increased expression of miR-21.

2. The method of claim 1, wherein the sample is determined to have increased expression of miR-21.

3. The method of claim 1, wherein the sample is determined not to have increased expression of miR-21 and further comprising identifying the patient as not having increased expression of miR-21.

4. The method of claim 1, further comprising obtaining the sample from the patient.

5. The method of claim 1, wherein the noncancerous sample is a benign thyroid sample.

6. The method of claim 1, further comprising measuring the expression level of miR-222.

7. The method of claim 6, wherein the sample is determined to have increased expression of miR-222.

8. The method of claim 1, further comprising measuring the expression level of one or more of the following miRNAs:

miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331.

9. The method of claim 7, further comprising measuring the expression level of one or more of the following miRNAs:

miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331.

10. A method for evaluating a thyroid sample in a patient comprising:

a) measuring an increased expression level of miR-21 in the sample compared to the expression level of miR-21 in a noncancerous thyroid sample; and

,

b) identifying the patient as having a marker for thyroid cancer.

11. The method of claim 10, further comprising measuring the expression level of miR-222 in the sample.

12. The method of claim 11, wherein the sample is determined to have increased expression of miR-222.

13. The method of claim 10, wherein the noncancerous thyroid sample comprises benign cells.

14. The method of claim 10, further comprising obtaining the sample from the thyroid of the patient.

15. The method of claim 10, further comprising measuring the expression level of one or more of the following miRNAs:

miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331.

16. The method of claim 11, further comprising measuring the expression level of one or more of the following miRNAs:

miR-10a, miR-15A, miR-22, miR-24, miR-29b, miR-30a, miR-30A-as, miR-31, miR-125, miR-126, miR-135A, miR-138, miR-145, miR-152, miR-183, miR-197, miR-199a, miR-199A-as, miR-200b, miR-203, miR-221, miR-223, miR-224, or miR-331.